Paclitaxel in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study

Objective. The goal of this study was to estimate the clinical activity of paclitaxel in patients with persistent or recurrent carcinosarcoma of the uterus who have failed other treatments. Methods. The Gynecologic Oncology Group (GOG) conducted a phase II study of paclitaxel 170 mg/m2 (135 mg/m2 in...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Gynecologic oncology Ročník 83; číslo 2; s. 268 - 270
Hlavní autori: Curtin, John P., Blessing, John A., Soper, John T., DeGeest, Koen
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: San Diego, CA Elsevier Inc 01.11.2001
Elsevier
Predmet:
Adult
Aged
Antineoplastic Agents, Phytogenic - adverse effects
Antineoplastic Agents, Phytogenic - therapeutic use
Biological and medical sciences
Carcinosarcoma - drug therapy
Drug Administration Schedule
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Humans
Infusions, Intravenous
Medical sciences
Middle Aged
Neoplasm Recurrence, Local - drug therapy
Paclitaxel - adverse effects
Paclitaxel - therapeutic use
Tumors
Uterine Neoplasms - drug therapy
Human
Antineoplastic agent
Relapse
Treatment resistance
Treatment efficiency
Malignant tumor
Female genital diseases
Chemotherapy
Treatment
Uterus
Taxane derivatives
Paclitaxel
Uterine diseases
Adult
Female
Spindle cell carcinoma
ISSN:0090-8258, 1095-6859
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Objective. The goal of this study was to estimate the clinical activity of paclitaxel in patients with persistent or recurrent carcinosarcoma of the uterus who have failed other treatments. Methods. The Gynecologic Oncology Group (GOG) conducted a phase II study of paclitaxel 170 mg/m2 (135 mg/m2 in those with prior irradiation) intravenously every 3 weeks in patients with histologic confirmation of carcinoma and measurable disease who had failed appropriate local therapy. Results. A total of 53 patients were entered into the study between September 1994 and January 1997; 44 patients were evaluable for response. The median age of the patients treated was 65 years (range: 38–79). Twenty-six patients had heterologous mixed mesodermal tumors (MMTs) and 18 patients had homologous tumors. A median of three courses were administered (range: 1–18). Fifteen patients had previous radiation therapy and 33 patients had failed prior chemotherapy. Eight patients (18.2%) had a response to paclitaxel: four patients had a complete response and four had a partial response. Neutropenia was the most common toxic effect. Conclusions. Paclitaxel had moderate activity in patients with carcinosarcoma of the uterus. The GOG is currently studying the combination of paclitaxel and ifosfamide versus ifosfamide alone for patients with advanced or recurrent carcinosarcoma of the uterus.
Bibliografia:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0090-8258
1095-6859
DOI:10.1006/gyno.2001.6256